List view / Grid view

doxorubicin

 

Combining soft-tissue cancer drugs improves survival

21 July 2016 | By Niamh Louise Marriott, Digital Content Producer

Scientists discovered that adding a novel monoclonal antibody therapy to traditional chemotherapy increased survival by nearly a year in patients with advanced sarcoma, a lethal soft-tissue cancer.

FDA grants Priority Review for olaratumab BLA

4 May 2016 | By Victoria White, Digital Content Producer

The US Food and Drug Administration (FDA) has granted Priority Review to Lilly’s biologics license application (BLA) for olaratumab, in combination with doxorubicin, for the potential treatment of people with advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery.